1
|
Turk Z, Armani A, Jafari-Gharabaghlou D, Madakbas S, Bonabi E, Zarghami N. A new insight into the early detection of HER2 protein in breast cancer patients with a focus on electrochemical biosensors approaches: A review. Int J Biol Macromol 2024; 272:132710. [PMID: 38825266 DOI: 10.1016/j.ijbiomac.2024.132710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2024] [Revised: 05/24/2024] [Accepted: 05/27/2024] [Indexed: 06/04/2024]
Abstract
Breast cancer is one of the leading causes of death in women and is a prevalent kind of cancerous growth, representing a substantial risk to women's health. Early detection of breast cancer is essential for effective treatment and improved survival rates. Biomarkers, active substances that signal the existence and advancement of a tumor, play a significant role in the early detection of breast cancer. Hence, accurate identification of biomarkers for tumors is crucial for diagnosing and treating breast cancer. However, the primary diagnostic methods used for the detection of breast cancer require specific equipment, skilled professionals, and specialized analysis, leading to elevated detection expenses. Regarding this obstacle, recent studies emphasize electrochemical biosensors as more advanced and sensitive detection tools compared to traditional methods. Electrochemical biosensors are employed to identify biomarkers that act as unique indicators for the onset, recurrence, and monitoring of therapeutic interventions for breast cancer. This study aims to provide a summary of the electrochemical biosensors that have been employed for the detection of breast cancer at an early stage over the past decade. Initially, the text provides concise information about breast cancer and tumor biomarkers. Subsequently, an in-depth analysis is conducted to systematically review the progress of electrochemical biosensors developed for the stable, specific, and sensitive identification of biomarkers associated with breast cancer. Particular emphasis was given to crucial clinical biomarkers, specifically the human epidermal growth factor receptor-2 (HER2). The analysis then explores the limitations and challenges inherent in the design of effective biosensors for diagnosing and treating breast cancer. Ultimately, we provided an overview of future research directions and concluded by outlining the advantages of electrochemical biosensor approaches.
Collapse
Affiliation(s)
- Zeynep Turk
- Department of Chemistry, Faculty of Science, Marmara University, Istanbul, Türkiye; Department of Analytical Chemistry, Faculty of Pharmacy, Istanbul Aydin University, Istanbul, Türkiye
| | - Arta Armani
- Department of Medical Biology and Genetics, Faculty of Medicine, Istanbul Aydin University, Istanbul, Türkiye
| | - Davoud Jafari-Gharabaghlou
- Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Seyfullah Madakbas
- Department of Chemistry, Faculty of Science, Marmara University, Istanbul, Türkiye
| | - Esat Bonabi
- Department of Medical Microbiology, Faculty of Medicine, Istanbul Aydin University, Istanbul, Türkiye
| | - Nosratollah Zarghami
- Department of Medical Biochemistry, Faculty of Medicine, Istanbul Aydin University, Istanbul, Türkiye.
| |
Collapse
|
2
|
Shaterabadi D, Zamani Sani M, Rahdan F, Taghizadeh M, Rafiee M, Dorosti N, Dianatinasab A, Taheri-Anganeh M, Asadi P, Khatami SH, Movahedpour A. MicroRNA biosensors in lung cancer. Clin Chim Acta 2024; 552:117676. [PMID: 38007056 DOI: 10.1016/j.cca.2023.117676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 11/18/2023] [Accepted: 11/20/2023] [Indexed: 11/27/2023]
Abstract
Lung cancer has been one of the leading causes of death over the past century. Unfortunately, the reliance on conventional methods to diagnose the phenotypic properties of tumors hinders early-stage cancer diagnosis. However, recent advancements in identifying disease-specific nucleotide biomarkers, particularly microRNAs, have brought us closer to early-stage detection. The roles of miR-155, miR-197, and miR-182 have been established in stage I lung cancer. Recent progress in synthesizing nanomaterials with higher conductivity has enhanced the diagnostic sensitivity of electrochemical biosensors, which can detect low concentrations of targeted biomarkers. Therefore, this review article focuses on exploring electrochemical biosensors based on microRNA in lung cancer.
Collapse
Affiliation(s)
- Donya Shaterabadi
- Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Maryam Zamani Sani
- Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Fereshteh Rahdan
- Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Mohammad Taghizadeh
- Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Maedeh Rafiee
- Department of Veterinary Sciences, University of Wyoming, 1174 Snowy Range Road, Laramie, WY 82070, USA
| | - Nafiseh Dorosti
- Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Aria Dianatinasab
- Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mortaza Taheri-Anganeh
- Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran
| | - Peyman Asadi
- Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Seyyed Hossein Khatami
- Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | | |
Collapse
|
3
|
Futane A, Narayanamurthy V, Jadhav P, Srinivasan A. Aptamer-based rapid diagnosis for point-of-care application. MICROFLUIDICS AND NANOFLUIDICS 2023; 27:15. [PMID: 36688097 PMCID: PMC9847464 DOI: 10.1007/s10404-022-02622-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Accepted: 12/31/2022] [Indexed: 05/31/2023]
Abstract
Aptasensors have attracted considerable interest and widespread application in point-of-care testing worldwide. One of the biggest challenges of a point-of-care (POC) is the reduction of treatment time compared to central facilities that diagnose and monitor the applications. Over the past decades, biosensors have been introduced that offer more reliable, cost-effective, and accurate detection methods. Aptamer-based biosensors have unprecedented advantages over biosensors that use natural receptors such as antibodies and enzymes. In the current epidemic, point-of-care testing (POCT) is advantageous because it is easy to use, more accessible, faster to detect, and has high accuracy and sensitivity, reducing the burden of testing on healthcare systems. POCT is beneficial for daily epidemic control as well as early detection and treatment. This review provides detailed information on the various design strategies and virus detection methods using aptamer-based sensors. In addition, we discussed the importance of different aptamers and their detection principles. Aptasensors with higher sensitivity, specificity, and flexibility are critically discussed to establish simple, cost-effective, and rapid detection methods. POC-based aptasensors' diagnostic applications are classified and summarised based on infectious and infectious diseases. Finally, the design factors to be considered are outlined to meet the future of rapid POC-based sensors.
Collapse
Affiliation(s)
- Abhishek Futane
- Fakulti Kejuruteraan Elektronik Dan Kejuruteraan Komputer, Universiti Teknikal Malaysia Melaka, Hang Tuah Jaya, Durian Tunggal, 76100 Melaka, Malaysia
| | - Vigneswaran Narayanamurthy
- Advance Sensors and Embedded Systems (ASECs), Centre for Telecommunication Research and Innovation, Fakulti Teknologi Kejuruteraan Elektrik Dan Elektronik, Universiti Teknikal Malaysia Melaka, Hang Tuah Jaya, Durian Tunggal, 76100 Melaka, Malaysia
- Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India
| | - Pramod Jadhav
- Faculty of Civil Engineering Technology, Universiti Malaysia Pahang (UMP) Lebuhraya Tun Razak, Gambang, 26300 Kuantan, Pahang Malaysia
- InnoFuTech, No 42/12, 7Th Street, Vallalar Nagar, Chennai, Tamil Nadu 600072 India
| | - Arthi Srinivasan
- Faculty of Chemical and Process Engineering Technology, University Malaysia Pahang (UMP), Lebuhraya Tun Razak, Gambang, 26300 Kunatan, Pahang Malaysia
| |
Collapse
|
4
|
Kadhim MM, Rheima AM, Abbas ZS, Jlood HH, Hachim SK, Kadhum WR, kianfar E. Evaluation of a biosensor-based graphene oxide-DNA nanohybrid for lung cancer. RSC Adv 2023; 13:2487-2500. [PMID: 36741187 PMCID: PMC9843741 DOI: 10.1039/d2ra05808a] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Accepted: 01/05/2023] [Indexed: 01/18/2023] Open
Abstract
Lung cancer is nowadays among the most prevalent diseases worldwide and features the highest mortality rate among various cancers, indicating that early diagnosis of the disease is of paramount importance. Given that the conventional methods of cancer detection are expensive and time-consuming, special attention has been paid to the provision of less expensive and faster techniques. In recent years, the dramatic advances in nanotechnology and the development of various nanomaterials have led to activities in this context. Recent studies indicate that the graphene oxide (GO) nanomaterial has high potential in the design of nano biosensors for lung cancer detection owing to its unique properties. In the current article, a nano biosensor based on a DNA-GO nanohybrid is introduced to detect deletion mutations causing lung cancer. In this method, mutations were detected using a FAM-labeled DNA probe with fluorescence spectrometry. GO was synthesized according to Hummers' method and examined and confirmed using Fourier Transform Infrared (FT-IR) Spectrometry and UV-vis spectrometry methods and Transmission Electron Microscopy (TEM) images.
Collapse
Affiliation(s)
- Mustafa M. Kadhim
- Medical Laboratory Techniques Department, Al-Farahidi UniversityBaghdad 10022Iraq
| | - Ahmed Mahdi Rheima
- Department of Chemistry, College of Science, Mustansiriyah UniversityBaghdadIraq
| | | | | | - Safa K. Hachim
- College of Technical Engineering, The Islamic UniversityNajafIraq,Medical Laboratory Techniques Department, Al-Turath University CollegeIraqBaghdad
| | - Wesam R. Kadhum
- Department of Pharmacy, Kut University CollegeKut 52001WasitIraq
| | - Ehsan kianfar
- Istanbul Medeniyet UniversityIstanbulTurkey+90 917-744-1049,Department of Chemical Engineering, Islamic Azad UniversityArak BranchArakIran,Young Researchers and Elite Club, Islamic Azad UniversityGachsaran BranchGachsaranIran,Department of Chemistry, Islamic Azad UniversitySousangerd BranchSousangerdIran
| |
Collapse
|
5
|
Sardarabadi P, Kojabad AA, Jafari D, Liu CH. Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC). BIOSENSORS 2021; 11:394. [PMID: 34677350 PMCID: PMC8533977 DOI: 10.3390/bios11100394] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 10/12/2021] [Accepted: 10/12/2021] [Indexed: 12/12/2022]
Abstract
Globally, non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths. Despite advancements in chemotherapy and targeted therapies, the 5-year survival rate has remained at 16% for the past forty years. Minimal residual disease (MRD) is described as the existence of either isolated tumour cells or circulating tumour cells in biological liquid of patients after removal of the primary tumour without any clinical signs of cancer. Recently, liquid biopsy has been promising as a non-invasive method of disease monitoring and treatment guidelines as an MRD marker. Liquid biopsy could be used to detect and assess earlier stages of NSCLC, post-treatment MRD, resistance to targeted therapies, immune checkpoint inhibitors (ICIs) and tumour mutational burden. MRD surveillance has been proposed as a potential marker for lung cancer relapse. Principally, biosensors provide the quantitative analysis of various materials by converting biological functions into quantifiable signals. Biosensors are usually operated to detect antibodies, enzymes, DNA, RNA, extracellular vesicles (EVs) and whole cells. Here, we present a category of biosensors based on the signal transduction method for identifying biosensor-based biomarkers in liquid biopsy specimens to monitor lung cancer treatment.
Collapse
Affiliation(s)
- Parvaneh Sardarabadi
- Institute of Nanoengineering and Microsystems, National Tsing Hua University, Hsinchu 30044, Taiwan;
| | - Amir Asri Kojabad
- Department of Hematology, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran 14535, Iran;
| | - Davod Jafari
- Department of Medical Biotechnology, School of Allied Medicine, Iran University of Medical Sciences, Tehran 14535, Iran;
| | - Cheng-Hsien Liu
- Institute of Nanoengineering and Microsystems, National Tsing Hua University, Hsinchu 30044, Taiwan;
- Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu 30044, Taiwan
| |
Collapse
|
6
|
Bräuer B, Unger C, Werner M, Lieberzeit PA. Biomimetic Sensors to Detect Bioanalytes in Real-Life Samples Using Molecularly Imprinted Polymers: A Review. SENSORS 2021; 21:s21165550. [PMID: 34450992 PMCID: PMC8400518 DOI: 10.3390/s21165550] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 08/12/2021] [Accepted: 08/15/2021] [Indexed: 01/16/2023]
Abstract
Molecularly imprinted polymers (MIPs) come with the promise to be highly versatile, useful artificial receptors for sensing a wide variety of analytes. Despite a very large body of literature on imprinting, the number of papers addressing real-life biological samples and analytes is somewhat limited. Furthermore, the topic of MIP-based sensor design is still, rather, in the research stage and lacks wide-spread commercialization. This review summarizes recent advances of MIP-based sensors targeting biological species. It covers systems that are potentially interesting in medical applications/diagnostics, in detecting illicit substances, environmental analysis, and in the quality control of food. The main emphasis is placed on work that demonstrates application in real-life matrices, including those that are diluted in a reasonable manner. Hence, it does not restrict itself to the transducer type, but focusses on both materials and analytical tasks.
Collapse
|
7
|
Quartz Crystal Microbalance (QCM) Based Biosensor Functionalized by HER2/neu Antibody for Breast Cancer Cell Detection. CHEMOSENSORS 2021. [DOI: 10.3390/chemosensors9040080] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The heterogeneity and metastatic features of cancer cells lead to a great number of casualties in the world. Additionally, its diagnosis as well as its treatment is highly expensive. Therefore, development of simple but effective diagnostic systems which detect the molecular markers of cancer is of great importance. The molecular changes on cancer cell membranes serve as targets, such as HER2/neu receptor which is detected on the surface of highly metastatic breast cancer cells. We have aimed to develop a specific and simple quartz crystal microbalance (QCM)-based system to identify HER2/neu expressing breast cancer cells via a receptor-specific monoclonal antibody. First, the QCM chip was coated with polymeric nanoparticles composed of hydroxyethylmethacrylate (HEMA) and ethylene glycol dimethacrylate (EDMA). The nanoparticle coated QCM chip was then functionalized by binding of HER2/neu antibody. The breast cancer cells with/without HER2/neu receptor expression, namely, SKBR3, MDA-MB 231 and also mouse fibroblasts were passed over the chip at a rate of 10–500 cells/mL and the mass changes (Δm) on cell/cm2 unit surface of sensor were detected in real-time. The detection limit of the system was 10 cells/mL. Thus, this QCM-based HER2/neu receptor antibody functionalized system might be used effectively in the detection of HER2/neu expressing SKBR3 breast cancer cells.
Collapse
|
8
|
Dai GH, Chen X, Ren ZM, Dai CJ, Tong YL, Chai KQ. Myricanol 5-fluorobenzyloxy ether regulation of survivin pathway inhibits human lung adenocarcinoma A549 cells growth in vitro. BMC Complement Med Ther 2020; 20:269. [PMID: 32883260 PMCID: PMC7470448 DOI: 10.1186/s12906-020-03062-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Accepted: 08/28/2020] [Indexed: 12/03/2022] Open
Abstract
Background This study aimed to explore the growth inhibitory effect of myricanol 5-fluorobenzyloxy ether (5FEM) and its underlying mechanisms in human lung adenocarcinoma A549 cells in vitro. Methods 5FEM was obtained by the chemical modification of myricanol with fluorobenzyloxy ether at the OH(5) position. The cytotoxicity, cell apoptosis, cell cycle, mitochondrial membrane potential (ΔΨm), scratch test, colony formation, and the expression levels of the key survivin pathway-related genes in A549 were evaluated. Results 5FEM could significantly inhibit A549 cell growth; induce cell apoptosis; increase G0/G1 population; reduce ΔΨm; inhibit cell migration and colony formation; upregulate caspase-9, P21, and Bax expression levels; and downregulate PARP, survivin, and Bcl-2 expression level. Conclusion These results enhanced our understanding of 5FEM and aid the discovery of novel myricanol derivatives as potential antitumor agents.
Collapse
Affiliation(s)
- Guan-Hai Dai
- Zhejiang Academy of Traditional Chinese Medicine, Institute of Basic Medicine, Hangzhou, 310007, China.
| | - Xuan Chen
- Zhejiang Academy of Traditional Chinese Medicine, Institute of Basic Medicine, Hangzhou, 310007, China
| | - Ze-Ming Ren
- Zhejiang Academy of Traditional Chinese Medicine, Institute of Basic Medicine, Hangzhou, 310007, China
| | - Chen-Jie Dai
- Zhejiang University-University of Edinburgh Institute, Zhejiang University, Haining, 314400, China
| | - Ye-Ling Tong
- Zhejiang Academy of Traditional Chinese Medicine, Institute of Basic Medicine, Hangzhou, 310007, China
| | - Ke-Qun Chai
- Oncology Department, Tongde Hospital of Zhejiang Province, Hangzhou, 310012, China.
| |
Collapse
|
9
|
Sheervalilou R, Shahraki O, Hasanifard L, Shirvaliloo M, Mehranfar S, Lotfi H, Pilehvar-Soltanahmadi Y, Bahmanpour Z, Zadeh SS, Nazarlou Z, Kangarlou H, Ghaznavi H, Zarghami N. Electrochemical Nano-biosensors as Novel Approach for the Detection of Lung Cancer-related MicroRNAs. Curr Mol Med 2019; 20:13-35. [DOI: 10.2174/1566524019666191001114941] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 08/22/2019] [Accepted: 09/03/2019] [Indexed: 12/12/2022]
Abstract
In both men and women around the world, lung cancer accounts as the
principal cause of cancer-related death after breast cancer. Therefore, early detection of
the disease is a cardinal step in improving prognosis and survival of patients. Today, the
newly-defined microRNAs regulate about 30 to 60 percent of the gene expression.
Changes in microRNA Profiles are linked to numerous health conditions, making them
sophisticated biomarkers for timely, if not early, detection of cancer. Though evaluation
of microRNAs in real samples has proved to be rather challenging, which is largely
attributable to the unique characteristics of these molecules. Short length, sequence
similarity, and low concentration stand among the factors that define microRNAs.
Recently, diagnostic technologies with a focus on wide-scale point of care have recently
garnered attention as great candidates for early diagnosis of cancer. Electrochemical
nano-biosensors have recently garnered much attention as a molecular method,
showing great potential in terms of sensitivity, specificity and reproducibility, and last but
not least, adaptability to point-of-care testing. Application of nanoscale materials in
electrochemical devices as promising as it is, brings multiplexing potential for conducting
simultaneous evaluations on multiple cancer biomarkers. Thanks to their enthralling
properties, these materials can be used to improve the efficiency of cancer diagnostics,
offer more accurate predictions of prognosis, and monitor response to therapy in a more
efficacious way. This article presents a concise overview of recent advances in the
expeditiously evolving area of electrochemical biosensors for microRNA detection in
lung cancer.
Collapse
Affiliation(s)
| | - Omolbanin Shahraki
- Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
| | - Leili Hasanifard
- Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Milad Shirvaliloo
- Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sahar Mehranfar
- Department of Genetics and Immunology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
| | - Hajie Lotfi
- Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Younes Pilehvar-Soltanahmadi
- Cellular and Molecular Research Center, Research Institute for Cellular and Molecular Medicine, Urmia University of Medical Sciences, Urmia, Iran
| | - Zahra Bahmanpour
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sadaf Sarraf Zadeh
- Neurosciences Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran
| | - Ziba Nazarlou
- Material Engineering Department, College of Science Koç University, Istanbul 34450, Turkey
| | - Haleh Kangarlou
- Department of Physics, Urmia Branch, Islamic Azad University, Urmia, Iran
| | - Habib Ghaznavi
- Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
| | - Nosratollah Zarghami
- Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
10
|
Yadav S, Kashaninejad N, Masud MK, Yamauchi Y, Nguyen NT, Shiddiky MJ. Autoantibodies as diagnostic and prognostic cancer biomarker: Detection techniques and approaches. Biosens Bioelectron 2019; 139:111315. [DOI: 10.1016/j.bios.2019.111315] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Revised: 05/07/2019] [Accepted: 05/08/2019] [Indexed: 01/25/2023]
|
11
|
A DNA based visual and colorimetric aggregation assay for the early growth factor receptor (EGFR) mutation by using unmodified gold nanoparticles. Mikrochim Acta 2019; 186:546. [DOI: 10.1007/s00604-019-3696-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Accepted: 07/08/2019] [Indexed: 02/06/2023]
|
12
|
Optical Biomarker-based Biosensors for Cancer/Infectious Disease Medical Diagnoses. Appl Immunohistochem Mol Morphol 2019; 27:278-286. [DOI: 10.1097/pai.0000000000000586] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
13
|
Hosseini SM, Soltani BM, Tavallaei M, Mowla SJ, Tafsiri E, Bagheri A, Khorshid HRK. Clinically Significant Dysregulation of hsa-miR-30d-5p and hsa-let-7b Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer. Avicenna J Med Biotechnol 2018; 10:98-104. [PMID: 29849986 PMCID: PMC5960066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
BACKGROUND The cyclin E2 (CYCE2) is an important regulator in the progression and development of NSCLC, and its ectopic expression promoted the proliferation, invasion, and migration in several tumors, including Non-Small Cell Lung Cancer (NSCLC). However, the upregulation of CYCE2 in NSCLC cells suggested that it has a key role in tumorigenicity. In addition, the RAS family proteins as oncoproteins were activated in many major tumor types and its suitability as the therapeutic target in NSCLC was proposed. Considering the crucial role of microRNAs, it was hypothesized that altered expression of hsa-miR-30d-5p and hsa-let-7b might provide a reliable diagnostic tumor marker for diagnosis of NSCLC. METHOD Real-time RT-PCR approach could evaluate the expression alteration of hsa-miR-30d-5p and hsa-let-7b and it was related to the surgically resected tissue of 24 lung cancer patients and 10 non-cancerous patients. The miRNAs expression was associated with clinicopathological features of the patients. RESULTS Hsa-miR-30d showed a significant downregulation (p=0.0382) in resected tissue of NSCLC patients compared with control group. Its expression level could differentiate different stages of malignancies from each other. The ROC curve analysis gave it an AUC=0.73 (p=0.037) which was a good score as a reliable biomarker. In contrast, hsa-let-7b was significantly overexpressed in tumor samples (p=0.03). Interestingly, our findings revealed a significant association of hsa-let-7b in adenocarcinoma tumors, compared to Squamous Cell Carcinomas (SCC) (p<0.05). Also, analysis of ROC curve of hsa-let-7b (AUC=0.74, p-value=0.042) suggests that it could be as a suitable biomarker for NSCLC. CONCLUSION Together, these results suggest a possible tumor suppressor role for hsa-miR-30d in lung tumor progression and initiation. Moreover, upregulation of hsa-let-7b was associated with the tumor type.
Collapse
Affiliation(s)
- Sayed Mostafa Hosseini
- Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
| | - Bahram Mohammad Soltani
- Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran,Corresponding author: Bahram Mohammad Soltani, Ph.D., Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran Tel: +98 21 82883464 Fax: +98 21 82884717 E-mail:
| | - Mahmoud Tavallaei
- Human Genetic Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Seyed Javad Mowla
- Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
| | - Elham Tafsiri
- Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
| | - Abouzar Bagheri
- Department of Clinical Biochemistry and Genetics, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | | |
Collapse
|
14
|
Microfluidic technologies for anticancer drug studies. Drug Discov Today 2017; 22:1654-1670. [DOI: 10.1016/j.drudis.2017.06.010] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Revised: 03/29/2017] [Accepted: 06/28/2017] [Indexed: 01/09/2023]
|
15
|
Wang L. Screening and Biosensor-Based Approaches for Lung Cancer Detection. SENSORS (BASEL, SWITZERLAND) 2017; 17:E2420. [PMID: 29065541 PMCID: PMC5677261 DOI: 10.3390/s17102420] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Revised: 10/17/2017] [Accepted: 10/18/2017] [Indexed: 02/07/2023]
Abstract
Early diagnosis of lung cancer helps to reduce the cancer death rate significantly. Over the years, investigators worldwide have extensively investigated many screening modalities for lung cancer detection, including computerized tomography, chest X-ray, positron emission tomography, sputum cytology, magnetic resonance imaging and biopsy. However, these techniques are not suitable for patients with other pathologies. Developing a rapid and sensitive technique for early diagnosis of lung cancer is urgently needed. Biosensor-based techniques have been recently recommended as a rapid and cost-effective tool for early diagnosis of lung tumor markers. This paper reviews the recent development in screening and biosensor-based techniques for early lung cancer detection.
Collapse
Affiliation(s)
- Lulu Wang
- School of Instrument Science and Opto-electronics Engineering, Hefei University of Technology, Hefei 230009, China.
- Institute of Biomedical Technologies, Auckland University of Technology, Auckland 1142, New Zealand.
| |
Collapse
|
16
|
Zhou Q, Huang SX, Zhang F, Li SJ, Liu C, Xi YY, Wang L, Wang X, He QQ, Sun CC, Li DJ. MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer. Cell Prolif 2017; 50. [PMID: 28990243 DOI: 10.1111/cpr.12394] [Citation(s) in RCA: 76] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2017] [Accepted: 09/09/2017] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Lung cancer is still one of the most serious causes of cancer-related deaths all over the world. MicroRNAs (miRNAs) are defined as small non-coding RNAs which could play a pivotal role in post-transcriptional regulation of gene expression. Increasing evidence demonstrated dysregulation of miRNA expression associates with the development and progression of NSCLC. AIMS To emphasize a variety of tissue-specific miRNAs, circulating miRNAs and miRNA-derived exosomes could be used as potential diagnostic and therapeutic biomarkers in NSCLC patients. MATERIALS & METHODS In the current review, we paid attention to the significant discoveries of preclinical and clinical studies, which performed on tissue-specific miRNA, circulating miRNA and exosomal miRNA. The related studies were obtained through a systematic search of Pubmed, Web of Science, Embase. RESULTS A variety of tissue-specific miRNAs and circulating miRNAs with high sensitivity and specificity which could be used as potential diagnostic and therapeutic biomarkers in NSCLC patients. In addition, we emphasize that the miRNA-derived exosomes become novel diagnostic biomarkers potentially in these patients with NSCLC. CONCLUSION MiRNAs have emerged as non-coding RNAs, which have potential to be candidates for the diagnosis and therapy of NSCLC.
Collapse
Affiliation(s)
- Qun Zhou
- Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, Hubei, 430071, China
| | - Shao-Xin Huang
- Department of Social Medicine and Public Health, School of Basic Medical Science, Jiujiang University, Jiujiang, Jiangxi, China
| | - Feng Zhang
- Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, Hubei, 430071, China
| | - Shu-Jun Li
- Wuhan Hospital for the Prevention and Treatment of Occupational Diseases, Wuhan, 430022, Hubei, China
| | - Cong Liu
- Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, Hubei, 430071, China
| | - Yong-Yong Xi
- Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, Hubei, 430071, China
| | - Liang Wang
- Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, Hubei, 430071, China
| | - Xin Wang
- Department of Social Medicine and Public Health, School of Basic Medical Science, Jiujiang University, Jiujiang, Jiangxi, China
| | - Qi-Qiang He
- Department of School of Public Health, Wuhan University, Wuhan, Hubei, 430071, China
| | - Cheng-Cao Sun
- Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, Hubei, 430071, China
| | - De-Jia Li
- Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, Hubei, 430071, China
| |
Collapse
|
17
|
Zamay GS, Zamay TN, Kolovskii VA, Shabanov AV, Glazyrin YE, Veprintsev DV, Krat AV, Zamay SS, Kolovskaya OS, Gargaun A, Sokolov AE, Modestov AA, Artyukhov IP, Chesnokov NV, Petrova MM, Berezovski MV, Zamay AS. Electrochemical aptasensor for lung cancer-related protein detection in crude blood plasma samples. Sci Rep 2016; 6:34350. [PMID: 27694916 PMCID: PMC5046130 DOI: 10.1038/srep34350] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2016] [Accepted: 09/09/2016] [Indexed: 12/15/2022] Open
Abstract
The development of an aptamer-based electrochemical sensor for lung cancer detection is presented in this work. A highly specific DNA-aptamer, LC-18, selected to postoperative lung cancer tissues was immobilized onto a gold microelectrode and electrochemical measurements were performed in a solution containing the redox marker ferrocyanide/ferricyanide. The aptamer protein targets were harvested from blood plasma of lung cancer patients by using streptavidin paramagnetic beads and square wave voltammetry of the samples was performed at various concentrations. In order to enhance the sensitivity of the aptasensor, silica-coated iron oxide magnetic beads grafted with hydrophobic C8 and C4 alkyl groups were used in a sandwich detection approach. Addition of hydrophobic beads increased the detection limit by 100 times. The detection limit of the LC-18 aptasensor was enhanced by the beads to 0.023 ng/mL. The formation of the aptamer – protein – bead sandwich on the electrode surface was visualized by electron microcopy. As a result, the electrochemical aptasensor was able to detect cancer-related targets in crude blood plasma of lung cancer patients.
Collapse
Affiliation(s)
- Galina S Zamay
- Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenecki, Laboratory for Biomolecular and medical technologies, 1 P. Zheleznyaka, Krasnoyarsk 660022, Russia.,Institute of Chemistry and Chemical Technology of the Siberian Branch of the Russian Academy of Science, 50/24, Akademgorodok, Krasnoyarsk, 660036, Russia
| | - Tatiana N Zamay
- Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenecki, Laboratory for Biomolecular and medical technologies, 1 P. Zheleznyaka, Krasnoyarsk 660022, Russia
| | | | - Alexandr V Shabanov
- Krasnoyarsk Research Center Siberian branch of Russian Academy of Science 50, Akademgorodok, Krasnoyarsk, 660036, Russia
| | - Yury E Glazyrin
- Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenecki, Laboratory for Biomolecular and medical technologies, 1 P. Zheleznyaka, Krasnoyarsk 660022, Russia.,Institute of Chemistry and Chemical Technology of the Siberian Branch of the Russian Academy of Science, 50/24, Akademgorodok, Krasnoyarsk, 660036, Russia
| | - Dmitry V Veprintsev
- Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenecki, Laboratory for Biomolecular and medical technologies, 1 P. Zheleznyaka, Krasnoyarsk 660022, Russia
| | - Alexey V Krat
- Krasnoyarsk Regional Clinical Cancer Center named after A.I. Kryzhanovsky 1, Smolenskaya, Krasnoyarsk, 660022, Russia
| | - Sergey S Zamay
- Krasnoyarsk Research Center Siberian branch of Russian Academy of Science 50, Akademgorodok, Krasnoyarsk, 660036, Russia
| | - Olga S Kolovskaya
- Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenecki, Laboratory for Biomolecular and medical technologies, 1 P. Zheleznyaka, Krasnoyarsk 660022, Russia
| | - Ana Gargaun
- University of Ottawa, Department of Chemistry, 10 Marie-Curie, D'Iorio Hall, Room 201 Ottawa, ON K1N 6N5, Canada
| | - Alexey E Sokolov
- Institute of Physics named after L.V. Kirenski Siberian Branch of Russian Academy of Science 50/38, Akademgorodok, Krasnoyarsk, 660036, Russia
| | - Andrey A Modestov
- Krasnoyarsk Regional Clinical Cancer Center named after A.I. Kryzhanovsky 1, Smolenskaya, Krasnoyarsk, 660022, Russia
| | - Ivan P Artyukhov
- Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenecki, Laboratory for Biomolecular and medical technologies, 1 P. Zheleznyaka, Krasnoyarsk 660022, Russia
| | - Nikolay V Chesnokov
- Institute of Chemistry and Chemical Technology of the Siberian Branch of the Russian Academy of Science, 50/24, Akademgorodok, Krasnoyarsk, 660036, Russia
| | - Marina M Petrova
- Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenecki, Laboratory for Biomolecular and medical technologies, 1 P. Zheleznyaka, Krasnoyarsk 660022, Russia
| | - Maxim V Berezovski
- University of Ottawa, Department of Chemistry, 10 Marie-Curie, D'Iorio Hall, Room 201 Ottawa, ON K1N 6N5, Canada
| | - Anna S Zamay
- Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenecki, Laboratory for Biomolecular and medical technologies, 1 P. Zheleznyaka, Krasnoyarsk 660022, Russia.,Institute of Chemistry and Chemical Technology of the Siberian Branch of the Russian Academy of Science, 50/24, Akademgorodok, Krasnoyarsk, 660036, Russia
| |
Collapse
|
18
|
Rezaei Kolahchi A, Khadem Mohtaram N, Pezeshgi Modarres H, Mohammadi MH, Geraili A, Jafari P, Akbari M, Sanati-Nezhad A. Microfluidic-Based Multi-Organ Platforms for Drug Discovery. MICROMACHINES 2016; 7:E162. [PMID: 30404334 PMCID: PMC6189912 DOI: 10.3390/mi7090162] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Revised: 08/23/2016] [Accepted: 08/24/2016] [Indexed: 12/18/2022]
Abstract
Development of predictive multi-organ models before implementing costly clinical trials is central for screening the toxicity, efficacy, and side effects of new therapeutic agents. Despite significant efforts that have been recently made to develop biomimetic in vitro tissue models, the clinical application of such platforms is still far from reality. Recent advances in physiologically-based pharmacokinetic and pharmacodynamic (PBPK-PD) modeling, micro- and nanotechnology, and in silico modeling have enabled single- and multi-organ platforms for investigation of new chemical agents and tissue-tissue interactions. This review provides an overview of the principles of designing microfluidic-based organ-on-chip models for drug testing and highlights current state-of-the-art in developing predictive multi-organ models for studying the cross-talk of interconnected organs. We further discuss the challenges associated with establishing a predictive body-on-chip (BOC) model such as the scaling, cell types, the common medium, and principles of the study design for characterizing the interaction of drugs with multiple targets.
Collapse
Affiliation(s)
- Ahmad Rezaei Kolahchi
- BioMEMS and Bioinspired Microfluidic Laboratory, Department of Mechanical and Manufacturing Engineering, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada.
| | - Nima Khadem Mohtaram
- Laboratory for Innovations in MicroEngineering (LiME), Department of Mechanical Engineering, University of Victoria, Victoria, BC V8P 5C2, Canada.
- Division of Medical Sciences, University of Victoria, Victoria, BC V8P 5C2, Canada.
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA.
| | - Hassan Pezeshgi Modarres
- BioMEMS and Bioinspired Microfluidic Laboratory, Department of Mechanical and Manufacturing Engineering, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada.
| | - Mohammad Hossein Mohammadi
- Department of Chemical and Petroleum Engineering, Sharif University of Technology, Azadi Ave., Tehran 11155-9516, Iran.
| | - Armin Geraili
- Department of Chemical and Petroleum Engineering, Sharif University of Technology, Azadi Ave., Tehran 11155-9516, Iran.
| | - Parya Jafari
- Department of Electrical Engineering, Sharif University of Technology, Azadi Ave., Tehran 11155-9516, Iran.
| | - Mohsen Akbari
- Laboratory for Innovations in MicroEngineering (LiME), Department of Mechanical Engineering, University of Victoria, Victoria, BC V8P 5C2, Canada.
- Division of Medical Sciences, University of Victoria, Victoria, BC V8P 5C2, Canada.
| | - Amir Sanati-Nezhad
- BioMEMS and Bioinspired Microfluidic Laboratory, Department of Mechanical and Manufacturing Engineering, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada.
- Center for Bioengineering Research and Education, Biomedical Engineering Program, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada.
| |
Collapse
|
19
|
The Extraordinary Progress in Very Early Cancer Diagnosis and Personalized Therapy: The Role of Oncomarkers and Nanotechnology. JOURNAL OF NANOTECHNOLOGY 2016. [DOI: 10.1155/2016/3020361] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The impact of nanotechnology on oncology is revolutionizing cancer diagnosis and therapy and largely improving prognosis. This is mainly due to clinical translation of the most recent findings in cancer research, that is, the application of bio- and nanotechnologies. Cancer genomics and early diagnostics are increasingly playing a key role in developing more precise targeted therapies for most human tumors. In the last decade, accumulation of basic knowledge has resulted in a tremendous breakthrough in this field. Nanooncology, through the discovery of new genetic and epigenetic biomarkers, has facilitated the development of more sensitive biosensors for early cancer detection and cutting-edge multifunctionalized nanoparticles for tumor imaging and targeting. In the near future, nanooncology is expected to enable a very early tumor diagnosis, combined with personalized therapeutic approaches.
Collapse
|
20
|
Mirzadeh Azad F, Naeli P, Malakootian M, Baradaran A, Tavallaei M, Ghanei M, Mowla SJ. Two lung development-related microRNAs, miR-134 and miR-187, are differentially expressed in lung tumors. Gene 2015; 577:221-6. [PMID: 26642897 DOI: 10.1016/j.gene.2015.11.040] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 11/18/2015] [Accepted: 11/26/2015] [Indexed: 01/04/2023]
Abstract
INTRODUCTION MicroRNAs (miRNAs) are involved in various cellular events needed for embryonic development and tumorigenesis. As some of the development-specific gene expression patterns could be observed in cancers, we speculated that the expression pattern of lung development-specific miRNAs miR-134 and miR-187 might be altered in lung tumor samples. Lung cancer is the first cause of cancer related deaths worldwide, mostly due to its late diagnosis. Therefore, finding a reliable diagnostic tumor marker, based on molecular profile of tumorigenesis, would be critical in lowering lung cancer mortality. METHODS We employed a real-time RT-PCR approach to evaluate the expression alteration of two lung development-related miRNAs in lung tumor tissues. The suitability of miRs expression alterations as lung tumor biomarkers was tested by receiver operating characteristic (ROC) curve analysis. The effect of miR-187 overexpression on a lung carcinoma cell cycle was assessed using flow cytometry analysis. RESULTS Our data revealed a significant upregulation (7.8 times, p<0.02) of miR-134 in lung tumors. However, its expression level failed to discriminate different tumor types and grades of malignancies from each other. Moreover, the ROC curves analysis did not give it a good score as a reliable biomarker (AUC=0.522, P=0.729). In contrast, miR-187 showed a significant down-regulation (P=0.008) in lung tumors. Similarly, its expression level failed to differentiate different tumor types or grades of malignancies. Nevertheless, ROC curve analysis gave it an AUC score of 0.669 (P=0.012), which suggests its suitability as a potential biomarker for lung cancer. Furthermore, ectopic expression of miR-187 in A549 cells caused a cell cycle arrest in G1 phase (P=0.013). CONCLUSION Altogether, our data demonstrated an altered expression of two development-related miRNAs namely miR-134 and miR-187 in lung tumors for the first time. Moreover we have shown that miR-134 and miR-187 expression alternation were in accordance with their approved regulatory roles, therefore these miRNAs could serve as new biomarkers with potential usefulness in lung cancer diagnosis and treatments. In addition, miR-187 expression in tumor cells could perturb cell cycle which supported its possible role as tumor suppressor.
Collapse
Affiliation(s)
- F Mirzadeh Azad
- Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
| | - P Naeli
- Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
| | - M Malakootian
- Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - A Baradaran
- Department of Pathology, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
| | - M Tavallaei
- Genetic Research Center, Baqiatallah University of Medical Sciences, Tehran, Iran
| | - M Ghanei
- Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - S J Mowla
- Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
| |
Collapse
|
21
|
Soares AC, Soares JC, Shimizu FM, Melendez ME, Carvalho AL, Oliveira ON. Controlled Film Architectures to Detect a Biomarker for Pancreatic Cancer Using Impedance Spectroscopy. ACS APPLIED MATERIALS & INTERFACES 2015; 7:25930-7. [PMID: 26539972 DOI: 10.1021/acsami.5b08666] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
The need for analytical devices for detecting cancer at early stages has motivated research into nanomaterials where synergy is sought to achieve high sensitivity and selectivity in low-cost biosensors. In this study, we developed a film architecture combining self-assembled monolayer (SAM) and layer-by-layer (LbL) films of polysaccharide chitosan and the protein concanavalin A, on which a layer of anti-CA19-9 antibody was adsorbed. Using impedance spectroscopy with this biosensor, we were capable of detecting low concentrations of the antigen CA19-9, an important biomarker for pancreatic cancer. The limit of detection of 0.69U/mL reached is sufficient for detecting pancreatic cancer at very early stages. The selectivity of the biosensor was inferred from a series of control experiments with samples of cell lines that were tested positive (HT29) and negative (SW620) for the biomarker CA19-9, in addition to the lack of changes in the capacitance value for other analytes and antigen that are not related to this type of cancer. The high sensitivity and selectivity are ascribed to the very specific antigen-antibody interaction, which was confirmed with PM-IRRAS and atomic force microscopy. Also significant is that used information visualization methods to show that different cell lines and commercial samples containing distinct concentrations of CA19-9 and other analytes can be easily distinguished from each other. These computational methods are generic and may be used in optimization procedures to tailor biosensors for specific purposes, as we demonstrated here by comparing the performance of two film architectures in which the concentration of chitosan was varied.
Collapse
Affiliation(s)
- Andrey C Soares
- São Carlos Institute of Physics, University of São Paulo , 13560-970 São Carlos, São Paulo Brazil
- São Carlos School of Engineering, University of São Paulo , 13560-000 São Carlos, São Paulo, Brazil
| | - Juliana C Soares
- São Carlos Institute of Physics, University of São Paulo , 13560-970 São Carlos, São Paulo Brazil
| | - Flavio M Shimizu
- São Carlos Institute of Physics, University of São Paulo , 13560-970 São Carlos, São Paulo Brazil
| | | | - André L Carvalho
- Barretos Cancer Hospital , 14784-400 Barretos, São Paulo, Brazil
| | - Osvaldo N Oliveira
- São Carlos Institute of Physics, University of São Paulo , 13560-970 São Carlos, São Paulo Brazil
| |
Collapse
|
22
|
Luo Y, Zhu X, Zhang P, Shen Q, Wang Z, Wen X, Wang L, Gao J, Dong J, Yang C, Wu T, Zhu Z, Tian Y. The clinical performance evaluation of novel protein chips for eleven biomarkers detection and the diagnostic model study. Int J Clin Exp Med 2015; 8:20413-20423. [PMID: 26884957 PMCID: PMC4723802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Accepted: 10/25/2015] [Indexed: 06/05/2023]
Abstract
We aimed to develop and validate two novel protein chips, which are based on microarray chemiluminescence immunoassay and can simultaneously detected 11 biomarkers, and then to evaluate their clinical diagnostic value by comparing with the traditional methods. Protein chips were evaluated for limit of detection, specificity, common interferences, linearity, precision and accuracy. 11 biomarkers were simultaneously detected by traditional methods and protein chips in 3683 samples, which included 1723 cancer patients, 1798 benign diseases patients and 162 healthy controls. After assay validation, protein chips demonstrated high sensitivity, high specificity, good linearity, low imprecision and were free of common interferences. Compared with the traditional methods, protein chips have good correlation in the detection of all the 13 kinds of biomarkers (r≥0.935, P<0.001). For specific cancer detection, there were no statistically significant differences between the traditional method and novel protein chips, except that male protein chip showed significantly better diagnostic value on NSE detection (P=0.004) but significantly worse value on pro-GRP detection (P=0.012), female chip showed significantly better diagnostic value on pro-GRP detection (P=0.005). Furthermore, both male and female multivariate diagnostic models had significantly better diagnostic value than single detection of PGI, PG II, pro-GRP, NSE and CA125 (P<0.05). In addition, male models had significantly better diagnostic value than single CA199 and free-PSA (P<0.05), while female models observed significantly better diagnostic value than single CA724 and β-HCG (P<0.05). For total disease or cancer detection, the AUC of multivariate logistic regression for the male and female disease detection was 0.981 (95% CI: 0.975-0.987) and 0.836 (95% CI: 0.798-0.874), respectively. While, that for total cancer detection was 0.691 (95% CI: 0.666-0.717) and 0.753 (95% CI: 0.731-0.775), respectively. The new designed protein chips are simple, multiplex and reliable clinical assays and the multi-parameter diagnostic models based on them could significantly improve their clinical performance.
Collapse
Affiliation(s)
- Yuan Luo
- Core Laboratory of Translational Medicine, State Key Laboratory of Kidney Disease, Chinese PLA General HospitalBeijing, P. R. China
| | - Xu Zhu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital&InstituteBeijing, P. R. China
| | - Pengjun Zhang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital&InstituteBeijing, P. R. China
| | - Qian Shen
- Department of Laboratory Diagnosis, Changhai Hospital, The Second Military Medical UniversityShanghai, P. R. China
| | - Zi Wang
- Core Laboratory of Translational Medicine, State Key Laboratory of Kidney Disease, Chinese PLA General HospitalBeijing, P. R. China
| | - Xinyu Wen
- Department of Clinical Biochemistry, Chinese PLA General HospitalBeijing, P. R. China
| | - Ling Wang
- Department of Clinical Biochemistry, Chinese PLA General HospitalBeijing, P. R. China
| | - Jing Gao
- Department of Clinical Biochemistry, Chinese PLA General HospitalBeijing, P. R. China
| | - Jin Dong
- Department of Clinical Biochemistry, Chinese PLA General HospitalBeijing, P. R. China
| | - Caie Yang
- Core Laboratory of Translational Medicine, State Key Laboratory of Kidney Disease, Chinese PLA General HospitalBeijing, P. R. China
| | - Tangming Wu
- Jiangsu Sunlant Bioengineering Co., LtdWuxi, P. R. China
| | - Zheng Zhu
- Jiangsu Sunlant Bioengineering Co., LtdWuxi, P. R. China
| | - Yaping Tian
- Core Laboratory of Translational Medicine, State Key Laboratory of Kidney Disease, Chinese PLA General HospitalBeijing, P. R. China
| |
Collapse
|
23
|
Kuemmel A, Simon P, Breitkreuz A, Röhlig J, Luxemburger U, Elsäßer A, Schmidt LH, Sebastian M, Sahin U, Türeci Ö, Buhl R. Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE). Lung Cancer 2015; 90:334-41. [PMID: 26350112 DOI: 10.1016/j.lungcan.2015.07.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Revised: 07/19/2015] [Accepted: 07/25/2015] [Indexed: 01/03/2023]
Abstract
OBJECTIVE The cancer/testis (C/T) antigen Transmembrane Phosphatase with TEnsin homology (TPTE) is aberrantly expressed in many tumors including lung cancer. In the present study, we analyzed TPTE-auto-antibodies in lung cancer patients. METHODS Using a crude-lysate ELISA, we analyzed a large cohort of 307 sera from lung cancer patients and 47 healthy donors for TPTE-specific autoantibodies. Sero-reactivity was correlated with clinical parameters and patients' survival. RESULTS TPTE-specific antibodies were detected in 41 of 307 (13.4%) sera from lung cancer patients. Based on an optimal cut-off value calculated by ROC curve analysis sensitivity for diagnosing lung cancer was 52% and specificity was 72%. TPTE sero-positivity was not associated with tumor stage, tumor histology, gender or age. Multivariate analysis indicated that TPTE sero-positivity is associated with prolonged survival in patients with lung cancer, but established prognostic factors for survival prediction such as stage and histology remain indispensable. CONCLUSION Autoantibodies against TPTE occur spontaneously in lung cancer patients. TPTE sero-reactivity has moderate sensitivity and specificity for diagnosing lung cancer and is a positive prognostic marker.
Collapse
Affiliation(s)
- Andreas Kuemmel
- Department of Hematology, Medical Oncology & Pneumology, University Medical Center Mainz, 55131 Mainz, Germany.
| | - Petra Simon
- Department of Hematology, Medical Oncology & Pneumology, University Medical Center Mainz, 55131 Mainz, Germany; TRON gGmbH, Translational Oncology at the University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany
| | - Andrea Breitkreuz
- Department of Hematology, Medical Oncology & Pneumology, University Medical Center Mainz, 55131 Mainz, Germany; TRON gGmbH, Translational Oncology at the University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany
| | - Julia Röhlig
- Department of Hematology, Medical Oncology & Pneumology, University Medical Center Mainz, 55131 Mainz, Germany
| | - Ulrich Luxemburger
- Department of Hematology, Medical Oncology & Pneumology, University Medical Center Mainz, 55131 Mainz, Germany; TRON gGmbH, Translational Oncology at the University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany
| | - Amelie Elsäßer
- Institute of Medical Biostatistics, Epidemiology and Informatics, Johannes Gutenberg-University, 55101 Mainz, Germany
| | - Lars Henning Schmidt
- Department of Medicine A, University Medical Center Muenster, 48149 Muenster, Germany
| | - Martin Sebastian
- Department of Medicine III, Goethe-University Frankfurt, 60590 Frankfurt am Main, Germany
| | - Ugur Sahin
- Department of Hematology, Medical Oncology & Pneumology, University Medical Center Mainz, 55131 Mainz, Germany; TRON gGmbH, Translational Oncology at the University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany
| | - Özlem Türeci
- Ganymed Pharmaceuticals AG, Freiligrathstr.12, 55131 Mainz, Germany
| | - Roland Buhl
- Department of Hematology, Medical Oncology & Pneumology, University Medical Center Mainz, 55131 Mainz, Germany
| |
Collapse
|
24
|
Doseeva V, Colpitts T, Gao G, Woodcock J, Knezevic V. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. J Transl Med 2015; 13:55. [PMID: 25880432 PMCID: PMC4335536 DOI: 10.1186/s12967-015-0419-y] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Accepted: 01/25/2015] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVES "PAULA's" test (Protein Assays Utilizing Lung cancer Analytes) is a novel multiplex immunoassay blood test that incorporates both tumor antigens and autoantibodies to determine the risk that lung cancer (LC) is present in individuals from a high-risk population. The test's performance characteristics were evaluated in a study using 380 retrospective clinical serum samples. METHODS PAULA's test is performed on the Luminex xMAP technology platform, and detects a panel of 3 tumor antigens (CEA, CA-125, and CYFRA 21-1) and 1 autoantibody marker (NY-ESO-1). A training set (n = 230) consisting of 115 confirmed diagnoses of non-small cell lung carcinoma (NSCLC) cases and 115 age- and smoking history-matched controls was used to develop the LC predictive model. Data from an independent matched validation set (n = 150) was then used to evaluate the model developed, and determine the ability of the test to distinguish NSCLC cases from controls. RESULTS The 4-biomarker panel was able to discriminate NSCLC cases from controls with 74% sensitivity, 80% specificity, and 0.81 AUC in the training set and with 77% sensitivity, 80% specificity, and 0.85 AUC in the independent validation set. The use of NY-ESO-1 autoantibodies substantially increased the overall sensitivity of NSCLC detection as compared to the 3 tumor markers alone. Overall, the multiplexed 4-biomarker panel assay demonstrated comparable performance to a previously employed 8-biomarker non-multiplexed assay. CONCLUSIONS These studies confirm the value of using a mixed panel of tumor antigens and autoantibodies in the early detection of NSCLC in high-risk individuals. The results demonstrate that the performance of PAULA's test makes it suitable for use as an aid to determine which high-risk patients need to be directed to appropriate noninvasive diagnostic follow-up testing, especially low-dose CT (LDCT).
Collapse
Affiliation(s)
- Victoria Doseeva
- 20/20 GeneSystems, 9430 Key West Avenue, Rockville, MD, 20850, USA.
| | - Tracey Colpitts
- Abbott Molecular Inc, 1300 E Touhy Avenue, Des Plaines, IL, 60018, USA.
| | - Grace Gao
- 20/20 GeneSystems, 9430 Key West Avenue, Rockville, MD, 20850, USA.
| | - Juliana Woodcock
- 20/20 GeneSystems, 9430 Key West Avenue, Rockville, MD, 20850, USA.
| | | |
Collapse
|
25
|
Myricanol induces apoptotic cell death and anti-tumor activity in non-small cell lung carcinoma in vivo. Int J Mol Sci 2015; 16:2717-31. [PMID: 25629230 PMCID: PMC4346861 DOI: 10.3390/ijms16022717] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2014] [Accepted: 01/21/2015] [Indexed: 12/17/2022] Open
Abstract
This study explored the inhibiting effect and mechanism of myricanol on lung adenocarcinoma A549 xenografts in nude mice. Forty nude mice with subcutaneous A549 xenografts were randomly divided into five groups: high-dose myricanol (40 mg/kg body weight) group; middle-dose myricanol (20 mg/kg body weight) group; low-dose myricanol (10 mg/kg body weight) group; polyethylene glycol 400 vehicle group (1 mL/kg); and tumor model group. Nude mice were sacrificed after 14 days of treatment and the tumor inhibition rate (TIR, %) was then calculated. The relative mRNA expression levels of Bax, Bcl-2, VEGF, HIF-1α, and survivin in the tumor tissues were determined by real-time PCR. TUNEL assay was applied to determine cellular apoptosis, while IHC test was performed to detect the protein expression levels of Bax, Bcl-2, VEGF, HIF-1α, and survivin. The TIR of the three myricanol-treated groups ranged from 14.9% to 38.5%. The IHC results showed that the protein expression of Bcl-2, VEGF, HIF-1α, and survivin were consistently downregulated, whereas that of Bax was upregulated after myricanol treatment. Myricanol also significantly upregulated the mRNA expression of Bax and downregulated that of Bcl-2, VEGF, HIF-1α, and survivin in a dose-dependent manner (p < 0.05 to 0.001). These results are consistent with those of IHC. The TUNEL assay results indicated that apoptotic-positive cells significantly increased in the myricanol-treated tumor tissues compared with the cells of the vehicle control group (p < 0.01 to 0.001). These data suggest that myricanol could significantly decelerate tumor growth in vivo by inducing apoptosis.
Collapse
|
26
|
Shen W, Yeo KH, Gao Z. A simple and highly sensitive fluorescence assay for microRNAs. Analyst 2015; 140:1932-8. [DOI: 10.1039/c4an02146k] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A simple and highly sensitive assay for miRNAs using magnetic bead-carried DNA probes coupled with DSN-facilitated isothermal target cycling is reported.
Collapse
Affiliation(s)
- Wei Shen
- Department of Chemistry
- National University of Singapore
- Singapore 117543
| | - Kiat Huei Yeo
- Department of Chemistry
- National University of Singapore
- Singapore 117543
| | - Zhiqiang Gao
- Department of Chemistry
- National University of Singapore
- Singapore 117543
| |
Collapse
|
27
|
Monteiro LDS, Bastos KX, Barbosa-Filho JM, de Athayde-Filho PF, Diniz MDFFM, Sobral MV. Medicinal Plants and Other Living Organisms with Antitumor Potential against Lung Cancer. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE : ECAM 2014; 2014:604152. [PMID: 25147575 PMCID: PMC4131470 DOI: 10.1155/2014/604152] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/23/2014] [Revised: 07/05/2014] [Accepted: 07/08/2014] [Indexed: 12/23/2022]
Abstract
Lung cancer is a disease with high morbidity and mortality rates. As a result, it is often associated with a significant amount of suffering and a general decrease in the quality of life. Herbal medicines are recognized as an attractive approach to lung cancer therapy with little side effects and are a major source of new drugs. The aim of this work was to review the medicinal plants and other living organisms with antitumor potential against lung cancer. The assays were conducted with animals and humans, and Lewis lung carcinoma was the most used experimental model. China, Japan, South Korea, and Ethiopia were the countries that most published studies of species with antitumor activity. Of the 38 plants evaluated, 27 demonstrated antitumor activity. In addition, six other living organisms were cited for antitumor activity against lung cancer. Mechanisms of action, combination with chemotherapeutic drugs, and new technologies to increase activity and reduce the toxicity of the treatment are discussed. This review was based on the NAPRALERT databank, Web of Science, and Chemical Abstracts. This work shows that natural products from plants continue to be a rich source of herbal medicines or biologically active compounds against cancer.
Collapse
Affiliation(s)
- Luara de Sousa Monteiro
- Department of Pharmaceutical Sciences, Federal University of Paraiba, 58051-900 João Pessoa, PB, Brazil
| | - Katherine Xavier Bastos
- Department of Pharmaceutical Sciences, Federal University of Paraiba, 58051-900 João Pessoa, PB, Brazil
| | - José Maria Barbosa-Filho
- Department of Pharmaceutical Sciences, Federal University of Paraiba, 58051-900 João Pessoa, PB, Brazil
| | | | | | - Marianna Vieira Sobral
- Department of Pharmaceutical Sciences, Federal University of Paraiba, 58051-900 João Pessoa, PB, Brazil
| |
Collapse
|